ArticleJournal of molecular medicine (Berlin, Germany)2026
Zinc-binding protein metallothionein 3 protects vascular smooth muscle cells from ferroptosis via blocking lysosomal degradation of GPX4.
Article in Journal of molecular medicine (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Aortic dissection (AD) is a life-threatening vascular emergency characterized by medial degeneration and vascular smooth muscle cell (VSMC) loss. Although disruption of zinc homeostasis has been reported in patients with AD, how zinc ions and their regulatory proteins influence VSMC survival and disease progression remains unknown. In this study, single-cell analyses revealed that ferroptosis and zinc-related pathways were significantly enriched in VSMCs from patients with AD, showing a strong correlation between the two processes, and zinc levels were markedly elevated in dissected aortas. Furthermore, zinc exposure promoted ferroptosis in cultured primary human aortic smooth muscle cells (HASMCs). By integrating transcriptomic data from AD tissues and VSMC ferroptosis models, metallothionein-3 (MT3), a zinc-binding protein, was identified as a candidate regulator. Functional studies demonstrated that MT3 overexpression markedly attenuated lipid peroxidation, reduced reactive oxygen species accumulation, and protected VSMCs from ferroptotic cell death, whereas MT3 knockdown increased oxidative stress and exacerbated ferroptotic injury. Mechanistically, MT3 directly interacted with glutathione peroxidase 4 (GPX4), enhanced its protein stability, without altering its transcriptional expression, and promoted glutathione synthesis, thereby activating the glutathione-GPX4 antioxidant defense pathway and mitigating oxidative injury. Notably, restoration of GPX4 effectively rescued the pro-ferroptotic effects of MT3 deficiency on HASMCs. These findings establish a previously unrecognized zinc-MT3-GPX4 axis as a critical determinant of VSMC ferroptosis in AD, linking zinc dysregulation to medial degeneration, and highlighting MT3 as a potential mechanistic candidate target to preserve vascular integrity and limit disease progression. KEY MESSAGES: Impaired zinc homeostasis is implicated in the development of aortic dissection (AD). Zinc-binding protein metallothionein 3 (MT3) mitigates lipid peroxidation and protects vascular smooth muscle cells from ferroptosis. MT3 directly interacts with glutathione peroxidase 4 (GPX4) to prevent its lysosomal degradation, thereby enhancing the glutathione-GPX4 antioxidant defense pathway. MT3 is a potential mechanistic candidate target for preserving vascular integrity and limiting AD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.